Preclinical animal study reveals low central brain penetration of galcanezumab in male rats, suggesting peripheral structures primarily mediate clinical efficacy.
The central levels of galcanezumab were relatively low, which would favor the dura mater and trigeminal ganglia as sites of action for its observed clinical efficacy. However, a central site of action cannot be excluded.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: